TESARO Inc (NASDAQ:TSRO) Director David M. Mott purchased 61,437 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were acquired at an average price of $58.83 per share, for a total transaction of $3,614,338.71. Following the purchase, the director now directly owns 12,825 shares of the company’s stock, valued at approximately $754,494.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
TESARO Inc (TSRO) traded down $1.91 on Wednesday, reaching $62.69. The company’s stock had a trading volume of 818,816 shares, compared to its average volume of 1,120,000. The firm has a market capitalization of $3,410.00, a price-to-earnings ratio of -6.83 and a beta of 1.40. TESARO Inc has a 52 week low of $52.20 and a 52 week high of $171.80. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.96). TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. The firm had revenue of $48.02 million for the quarter, compared to analyst estimates of $51.78 million. sell-side analysts predict that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
TSRO has been the topic of a number of recent research reports. Citigroup reiterated a “buy” rating and issued a $135.00 target price (down previously from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Morgan Stanley lowered their price objective on TESARO from $165.00 to $156.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 16th. HC Wainwright restated a “buy” rating and issued a $158.00 price objective on shares of TESARO in a research report on Friday, January 12th. Cowen reduced their target price on TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a research note on Tuesday, January 2nd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $150.00 price objective (down from $190.00) on shares of TESARO in a research note on Thursday, January 18th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $133.39.
Institutional investors have recently bought and sold shares of the stock. Toronto Dominion Bank boosted its stake in shares of TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares in the last quarter. Commonwealth Equity Services Inc purchased a new stake in shares of TESARO in the third quarter valued at approximately $222,000. Crossmark Global Holdings Inc. purchased a new stake in shares of TESARO in the third quarter valued at approximately $230,000. CIBC Asset Management Inc acquired a new position in TESARO during the third quarter worth $234,000. Finally, Exane Derivatives raised its holdings in TESARO by 137.1% during the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,123 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/14/insider-buying-tesaro-inc-tsro-director-buys-61437-shares-of-stock.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.